The differences in the frequencies of other common AML biomarkers (including NPM1, DNMT3A, IDH1, IDH2, TP53, KRAS, NRAS, RUNX1, and CEBPA) between the South Korean and other cohorts were not significant. This evidence concerns the gene NRAS and acute myeloid leukemia.